Goals · Specialty & Clinical
Glycemic control. Includes FDA-approved GLP-1 agonists, metformin-adjacent compounds.
Compounds linked to this goal in the catalogue, ordered by role — primary, then support, then optional. Click any card for the full mechanism, dosing, and evidence.
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Half-life: 6-8 days
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Half-life: 25-68 hours
KEDW Tetrapeptide | Pancreas Bioregulator
Half-life: Not established
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Half-life: ~6 days
GLP-1 Receptor Agonist | Weight Loss & Diabetes
Half-life: ~7 days (168 hours)
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
Half-life: ~5 days (120 hours)
No SARMs tagged for this goal yet.
No compounds tagged for this goal yet.